Market Closed -
Nasdaq
04:00:00 2024-05-17 pm EDT
5-day change
1st Jan Change
982.3
USD
+1.48%
+0.87%
+11.84%
Sales 2024 *
13.83B
Sales 2025 *
14.93B
Capitalization
106B
Net income 2024 *
3.96B
Net income 2025 *
4.42B
EV / Sales 2024 *
7.01
x
Net cash position
2024
*
9.08B
Net cash position
2025
*
14.86B
EV / Sales 2025 *
6.1
x P/E ratio 2024 *
28.7
x
P/E ratio 2025 *
25.6
x
Employees
13,677
Yield 2024 *
-
Yield 2025 *
-
Free-Float
78.33%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Regeneron Pharmaceuticals Insider Sold Shares Worth $22,355,714, According to a Recent SEC Filing
May. 17
MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $48,636,545, According to a Recent SEC Filing
May. 17
MT
Sector Update: Health Care Stocks Mixed Late Afternoon
May. 17
MT
Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,115 From $1,060
May. 17
MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $35,207,110, According to a Recent SEC Filing
May. 16
MT
Transcript : Regeneron Pharmaceuticals, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 09:00 AM
May. 14
Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Younger CRSwNP Group
May. 13
DJ
Regeneron Pharmaceuticals, Sanofi Say FDA Accepts Dupixent Supplemental Application for Priority Review
May. 13
MT
Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Dupixent
May. 13
CI
Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
May. 08
CI
UBS Raises Regeneron Pharmaceuticals Price Target to $1,124 From $1,099, Maintains Buy Rating
May. 07
MT
Deutsche Bank Adjusts Price Target on Regeneron Pharmaceuticals to $870 From $880, Hold Rating Kept
May. 03
MT
Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,126
May. 03
MT
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,183 From $1,177
May. 02
MT
Piper Sandler Adjusts Regeneron Pharmaceuticals' Price Target to $1,000.25 From $1,016
May. 02
MT
More news
Regeneron Pharmaceuticals Insider Sold Shares Worth $22,355,714, According to a Recent SEC Filing
May. 17
MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $48,636,545, According to a Recent SEC Filing
May. 17
MT
Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,115 From $1,060
May. 17
MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $35,207,110, According to a Recent SEC Filing
May. 16
MT
UBS Raises Regeneron Pharmaceuticals Price Target to $1,124 From $1,099, Maintains Buy Rating
May. 07
MT
More recommendations
1 day +1.48%
1 week +0.87%
Current month +10.29%
1 month +9.00%
3 months +3.61%
6 months +22.41%
Current year +11.84%
More quotes
Managers
Title Age Since
Founder
64
88-01-07
Chief Executive Officer
71
88-01-07
Director of Finance/CFO
54
02-12-31
Members of the board
Title Age Since
Director/Board Member
71
10-11-11
Chief Executive Officer
71
88-01-07
Director/Board Member
82
91-05-31
More insiders
Date
Price
Change
Volume
24-05-17
982.3
+1.48%
386,559
24-05-16
968
-1.05%
407,581
24-05-15
978.2
-0.65%
593,508
24-05-14
984.6
+0.79%
308,034
24-05-13
977
+0.32%
284,348
Delayed Quote
Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotes
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows:
- revenues from product sales (56.6%);
- revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%);
- other (3%): primarily revenues from sales of technology licenses and subcontracted research services.
At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
More about the company
Last Close Price
982.3
USD
Average target price
1,042
USD
Spread / Average Target
+6.03%
Consensus
1st Jan change
Capi.
+11.84% 106B +9.42% 115B -1.05% 21.96B -14.15% 21.84B -5.29% 19.21B -4.16% 18.08B -38.29% 17.71B +7.99% 14.32B +36.24% 12.42B -24.95% 8.23B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1